Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca’s John Rex joins UK biotech F2G

Takes up the role of chief medical officer at the UK company

F2G John RexJohn Rex has moved from AstraZeneca to F2G to become the Manchester, UK-based drug discovery firm's chief medical officer.

He was previously a senior vice president at AZ, where he served as head of infection within its global medicines development unit, and he has been a non-executive director at F2G since 2012.

Ian Nicholson, chief executive officer at F2G, said: “John's guidance and insight have been instrumental in shaping F2G's development and regulatory strategy. We are delighted that he is now able to increase his commitment to the company as we progress our new class of antifungal agents into our next clinical trials.”  

In his new role Rex will be tasked with helping move F2G's first-in-class antifungal F901218 through phase II clinical trials.

John Rex said: “I am delighted to have the opportunity to work more closely with F2G as we take the first orotomide antifungal forward through phase II and phase III. Just as with antibacterial resistance, antifungal resistance is a growing threat and F2G's discovery of an entirely novel class of IV/PO antifungal agent is a key part of the global response to this challenge.”

Prior to joining AstraZeneca in 2003, Rex was professor of medicine at the University of Texas Medical School and has previously served as the industry representative on the US FDA Anti-Infective Drug Advisory Committee.

5th December 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics